DraxImage of Kirkland, Canada, has received approval from the Canadian Nuclear Safety Commission for its BrachySeed implant for prostate cancer therapy, according to parent firm Draxis Health. The approval clears BrachySeed for sales in Canada, and shipments are set to begin this quarter, according to Draxis Health president and CEO Dr. Martin Barkin.
DraxImage received FDA and Nuclear Regulatory Commission approvals for BrachySeed in the third quarter. In collaboration with marketing partner Cytogen of Princeton, NJ, the firm expects to begin U.S. deliveries late this year.
By AuntMinnie.com staff writers
October 10, 2000
Related Reading
DraxImage gets NRC approval for BrachySeed, September 22, 2000
Draxis signs brachytherapy seed agreement with Cytogen, September 14, 2000
Draxis to emphasize radiopharmaceuticals, July 19, 2000
Copyright © 2000 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
